Reading WAY? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track WAY free→Reading WAY? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track WAY free→QuarterlyIQ Insights · WAY
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Results of Operations and Financial Condition. On April 29, 2026, Waystar Holding Corp. (the “Company”) issued a press release announcing earnings and other financial results for the fiscal quarter ended March 31, 2026. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference. The information in this Item 2.02, including the corresponding Exhibit 99.1, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exc…
Results of Operations and Financial Condition. On February 17, 2026, Waystar Holding Corp. (the “Company”) issued a press release announcing earnings and other financial results for the fiscal quarter and fiscal year ended December 31, 2025. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference. The information in this Item 2.02, including the corresponding Exhibit 99.1, is being furnished and shall not be deemed "filed" for purposes of Section 18…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On February 2, 2026, Eric (Ric) Sinclair III, Chief Business Officer of Waystar Holding Corp. (the “Company”), notified the Company of his intention to resign from the Company effective March 2, 2026 to accept a position at another company. Mr. Sinclair’s resignation is not the result of any disagreement with the Company or the Company’s Board of D…
Unregistered Sales of Equity Securities. Effective upon the completion of the acquisition of Iodine, the Company issued 16,639,906 shares of common stock, par value $0.01 per share, of the Company (“Company Common Stock”), to certain equityholders of Iodine in partial consideration for the Company’s acquisition of Iodine. The Company Common Stock was issued in reliance upon the exemption from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”), provi…
Entry into a Material Definitive Agreement. On October 1, 2025, certain subsidiaries of the Company entered into the Twelfth Amendment (“Amendment No. 12”) to the First Lien Credit Agreement, dated as of October 22, 2019 (as amended by the First Amendment thereto, dated as of December 2, 2019, the Second Amendment thereto, dated as of September 23, 2020, the Third Amendment thereto, dated as of March 24, 2021, the Fourth Amendment thereto, dated as of August 24, 2021, the Fifth Amendment ther…
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth above under
Other Events. On October 1, 2025, the Company completed the previously announced acquisition of Iodine. Pursuant to the Agreement and Plan of Merger, dated as of July 23, 2025 (the “Merger Agreement”), by and among the Company, Morton Merger Sub 1, Inc. (“Reverse Merger Sub”), Isotope Holding, LLC (“Forward Merger Sub”), Iodine, Iodine Software Parent, LLC and Shareholder Representative Services LLC, as the equityholder representative, the Company acquired Iodine through a sequence of mergers…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Effective upon the completion of the acquisition of Iodine, the board of directors of the Company (the “Board”) expanded the size of the Board from twelve directors to thirteen directors and appointed Lauren Young to serve as a Class II director. The Board determined Ms. Young to be deemed independent under the applicable rules and regulations of t…
Regulation FD Disclosure. On October 1, 2025, the Company issued a press release announcing the completion of the acquisition of Iodine. A copy of that press release is attached as Exhibit 99.1 hereto and is incorporated by reference herein. The information in this Item 7.01, including the corresponding Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities under that section and shall not be dee…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.